Texas is currently home to 4855 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Project Sueño: Sleep & Understanding Early Nutrition in Obesity
NCT06117631
Recruiting
The purpose of the study is to understand how mothers think and feel about feeding their babies and putting them to sleep, understand more about programs that can support mothers taking care of babies, and how professionals can be most helpful in helping mothers make decisions about their baby's feeding and sleeping. The overarching goal is to prevent early life obesity and progression to metabolic syndrome in high-risk populations, starting with healthy toddler weights by age 2 years.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
11/01/2023
Locations: CommUnity Care: North Central Health Center, Austin, Texas
Conditions: Infant Overweight, Infant Obesity, Infant Overnutrition, Infant Development, Metabolic Syndrome, Diabetes Mellitus Risk
Register for Updates
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
NCT04321954
Recruiting
This research is being done to evaluate the safety and efficacy of neoadjuvant lenvatinib on surgical outcomes of patients with invasive extrathyroidal differentiated thyroid cancer (DTC). This research study involves a study drug called lenvatinib
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2023
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Differentiated Thyroid Cancer, Advanced Cancer
Register for Updates
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
NCT05094804
Recruiting
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805 administered as a monotherapy and in combination with anti-cancer agents in subjects with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/31/2023
Locations: NEXT Austin, Austin, Texas
Conditions: Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Leiomyosarcoma, Liposarcoma
Register for Updates
Alternative Treatment Strategies for Stenotrophomonas Maltophilia Pneumonia
NCT06112938
Recruiting
Multi center, retrospective chart review of patients admitted to MHS hospitals from April 1, 2017 to March 31, 2022. Patients will be identified through the electronic medical record, and data from those that meet the study inclusion and exclusion criteria will be analyzed. Minimum inhibitory concentration (MIC) data will be interpreted per Clinical \& Laboratory Standards Institute (CLSI) standards to determine local patterns of resistance. Multivariable logistic regression will be performed to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2023
Locations: Methodist Dallas Medical Center, Dallas, Texas
Conditions: Stenotrophomonas Maltophilia Infection
Register for Updates
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
NCT05082519
Recruiting
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even those who start chemotherapy at a healthy weight. This study is being done to find out if caloric restriction achieved by a personalized nutritional menu and exercise plan during routine chemotherapy... Read More
Gender:
ALL
Ages:
Between 10 years and 25 years
Trial Updated:
10/25/2023
Locations: University of Texas, Southwestern, Dallas, Texas
Conditions: B-cell Acute Lymphoblastic Leukemia, Obesity
Register for Updates
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646
Recruiting
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared with placebo over a treatment period of 104 weeks in adult patients with FSGS who are being treated with an... Read More
Gender:
ALL
Ages:
Between 12 years and 80 years
Trial Updated:
10/24/2023
Locations: ACTION3 Investigational Site 2, Dallas, Texas
Conditions: FSGS
Register for Updates
Brain Metabolism Observed at 7 Tesla
NCT05085704
Recruiting
The goal is to develop methodology to monitor flux in the citric acid cycle in brain via 13C nuclear magnetic resonance (NMR) spectroscopy at 7 Tesla.
Gender:
ALL
Ages:
Between 16 years and 65 years
Trial Updated:
10/23/2023
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Glut1 Deficiency Syndrome 1, Glucose Metabolism Disorders, Epilepsy, Glut1 Deficiency Syndrome 1, Autosomal Recessive, Glucose Transporter Type 1 Deficiency Syndrome, Glucose Transporter Protein Type 1 Deficiency Syndrome, Glucose Transport Defect
Register for Updates
A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)
NCT04964518
Recruiting
This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy and PK of APG-2575 in combination with Azacitidine in the patients with AML/MPAL or MDS/CMML. The study consists of dose escalation (Part I) and dose expansion phase (Part II)
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
10/23/2023
Locations: MDACC, Houston, Texas
Conditions: AML, Adult
Register for Updates
Adaptation of Critical Time Intervention for Young Adults With MH Challenges
NCT06102850
Recruiting
Young adults experiencing homelessness have high rates of mental health conditions but low rates of service utilization and the point of transition from homelessness to supported housing provides a window of opportunity for intervention. The goal of this study is to adapt the evidenced-based intervention, Critical Time Intervention, for young adults with mental health conditions who are entering a rapid rehousing program and test the adapted intervention in a randomized feasibility pilot trial.... Read More
Gender:
ALL
Ages:
Between 18 years and 24 years
Trial Updated:
10/20/2023
Locations: Covenant House Texas, Houston, Texas
Conditions: Mental Disorder
Register for Updates
A Study of HB0045 Injection in Patients With Advanced Solid Tumors
NCT06056323
Recruiting
This is a phase I/II, open-label, multicenter study . During the study, subjects will be evaluated for safety, toxicity, tolerability, PK/PD, immunogenicity, biomarkers, and antitumor activity of HB0045. The phase I study will enroll up to 54 subjects with advanced solid tumors who have progressed on or after standard of care therapy and for whom there is no further treatment available that in the judgement of the patient's physician would be beneficial. One cycle is defined as 21 days.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/19/2023
Locations: UT M.D. Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumor, Adult
Register for Updates
A Clinical Study to Evaluate the Potential Role of ACTH Gel in Patients With Scleritis
NCT03465111
Recruiting
ATLAS study is a clinical trial to evaluate the potential role of subcutaneous adrenocorticotropic hormone (ACTH) gel in the management of non-infectious scleritis. Specifically, the ATLAS Study aims to evaluate the safety, tolerability and effect of 2 different dose regimens of ACTH gel administered by subcutaneous (SC) injection in patients with scleritis, over a period of 12 months. Scleritis is an inflammatory disease affecting the sclera (white outer coating of the eye), which causes blur... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/19/2023
Locations: Foresight Studies, LLC, San Antonio, Texas
Conditions: Scleritis
Register for Updates
Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy
NCT05995236
Recruiting
This study is a single-center registry study collecting clinical data regarding the treatment of PSMA-positive metastatic castration-resistant prostate cancer treated with PSMA radionuclide therapy per the treating physician's discretion. Clinical data from candidates for or who undergo the PSMA procedure at Methodist Dallas Medical Center from August 2022 to August 2027 will be collected after discharge and patients will undergo clinical follow-up per the treating physician's discretion.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/18/2023
Locations: Methodist Dallas Medical Center, Dallas, Texas
Conditions: Prostate Cancer
Register for Updates